EMJ Cardiology 10 [Supplement 1] . 2022

In this issue

In an interview conducted by EMJ, a leading expert from the field of cardiology and cardiovascular disease provided their perspectives on Phase II data and the design of the Phase II trial for aficamten. A cardiac myosin inhibitor, aficamten targets the underlying pathophysiology of hypertrophic cardiomyopathy.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given